Additional Genetic Risk Factors for Anthracycline-Induced Cardiotoxicity in Pediatric Cancer

被引：0
|
作者：
Scott, E. [1 ,2 ]
Drogemoller, B. [1 ,3 ]
Wright, G. [1 ,2 ]
Carleton, B. [1 ,2 ,4 ,5 ]
Ross, C. [1 ,2 ,3 ]
机构：
[1] BC Childrens Hosp, Res Inst, Dept Med Genet, Vancouver, BC, Canada
[2] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada
[3] Univ British Columbia, Fac Pharmaceut Sci, Vancouver, BC, Canada
[4] Univ British Columbia, Div Translat Therapeut, Dept Pediat, Vancouver, BC, Canada
[5] BC Childrens Hosp, Res Inst, Pharmaceut Outcomes Programme, Vancouver, BC, Canada
来源：
PEDIATRIC BLOOD & CANCER | 2020年 / 67卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
0270
引用
收藏
页码：S127 / S128
页数：2
相关论文
共 50 条
  • [21] Pharmacogenomic study of anthracycline-induced cardiotoxicity in Mexican pediatric patients
    Vargas-Neri, Jessica L.
    Carleton, Bruce
    Ross, Colin J.
    Medeiros, Mara
    Castaneda-Hernandez, Gilberto
    Clark, Patricia
    PHARMACOGENOMICS, 2022, 23 (04) : 291 - 301
  • [22] EVALUATION OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN CANCER-PATIENTS
    FIORIO, P
    RAVERA, D
    CAMPORA, E
    NOBILE, MT
    MELA, G
    PASTORINI, C
    BORZIANI, S
    JOURNAL OF NUCLEAR MEDICINE AND ALLIED SCIENCES, 1985, 29 (1-2): : 77 - 78
  • [23] Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
    Bansal, Neha
    Adams, M. Jacob
    Ganatra, Sarju
    Colan, Steven D.
    Aggarwal, Sanjeev
    Steiner, Rudolf
    Amdani, Shahnawaz
    Lipshultz, Emma R.
    Lipshultz, Steven E.
    CARDIO-ONCOLOGY, 2019, 5 (01)
  • [24] Pharmacogenomic screening for anthracycline-induced cardiotoxicity in childhood cancer
    Aminkeng, Folefac
    Ross, Colin J. D.
    Rassekh, Shahrad R.
    Rieder, Michael J.
    Bhavsar, Amit P.
    Sanatani, Shubhayan
    Bernstein, Daniel
    Hayden, Michael R.
    Amstutz, Ursula
    Carleton, Bruce C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 83 (05) : 1143 - 1145
  • [25] Strategies to prevent anthracycline-induced cardiotoxicity in cancer survivors
    Neha Bansal
    M. Jacob Adams
    Sarju Ganatra
    Steven D. Colan
    Sanjeev Aggarwal
    Rudolf Steiner
    Shahnawaz Amdani
    Emma R. Lipshultz
    Steven E. Lipshultz
    Cardio-Oncology, 5
  • [26] Recommendations for genetic testing to reduce the incidence of anthracycline-induced cardiotoxicity
    Aminkeng, Folefac
    Ross, Colin J. D.
    Rassekh, Shahrad R.
    Hwang, Soomi
    Rieder, Michael J.
    Bhavsar, Amit P.
    Smith, Anne
    Sanatani, Shubhayan
    Gelmon, Karen A.
    Bernstein, Daniel
    Hayden, Michael R.
    Amstutz, Ursula
    Carleton, Bruce C.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 82 (03) : 683 - 695
  • [27] A Genetic Variant in RARG Informs Anthracycline-Induced Cardiotoxicity Risk Status in Pediatric Patients and a Viable Cardiac Protection Strategy
    Hasbullah, J.
    Bhavsar, A.
    Gunaretnam, E.
    Carleton, B.
    Ross, C.
    PEDIATRIC BLOOD & CANCER, 2020, 67 : S127 - S127
  • [28] Discovery of Critical Transcription Factors as Biomarkers in Anthracycline-Induced Cardiotoxicity
    Faber, J.
    Asensio, J. Ochoteco
    Nguyen, N.
    Caiment, F.
    van den Beucken, T.
    TOXICOLOGY LETTERS, 2023, 384 : S79 - S80
  • [29] New Developments in Anthracycline-Induced Cardiotoxicity
    Mordente, A.
    Meucci, E.
    Silvestrini, A.
    Martorana, G. E.
    Giardina, B.
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (13) : 1656 - 1672
  • [30] Drug transporters and anthracycline-induced cardiotoxicity
    Huang, Kevin M.
    Hu, Shuiying
    Sparreboom, Alex
    PHARMACOGENOMICS, 2018, 19 (11) : 883 - 888
12345